The MPS I market is evolving through innovative enzyme therapies and emerging treatment modalities. Leading companies including Sanofi, Takeda, and BioMarin are pioneering novel enzyme replacements and advanced genetic interventions that enhance clinical efficacy and patient quality of life. Improved diagnostic protocols and multidisciplinary care approaches are optimizing management strategies for this progressive metabolic disorder.
View Full Analysis: https://shorturl.at/nNxbj
Comment
Share
